KaloBios Pharmaceuticals, Inc. KBIO
No live quote for KBIO yet.
- Market cap
- 64.08M
- EPS (ttm)
- -5.02
- Shares out
- 14.90M
- P/E ratio
- -0.86
- Volume
- 17.70K
- Avg volume
- 11.60K
- Open
- 4.75
- Previous close
- 4.49
- Beta
- 4.79
- Analysts
- Strong Buy
- Price target
- 5.00
Key statistics
- Enterprise value
- 64.51M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 326.75K
- Total cash
- 2.90M
- Total debt
- 1.24M
- Return on equity
- -1774.70%
- Short % of float
- 8.17%
- 50-day average
- 3.54
- 200-day average
- 3.62
Analyst view
Consensus: strong buy
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 29, 2014 | Needham | down | Buy | Hold |
| Mar 4, 2013 | Needham | init | — | Buy |
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. Its lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems. The company is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase I clinical trial in patients with chronic myelomonocytic leukemia; and ifabotuzumab that has completed Phase I/II clinical trial in multiple hematologic malignancies, as well as evaluating further studies of ifabotuzumab in rare solid tumors, such as glioblastoma, other brain cancers in children, and rare hematologic cancer indications. In addition, it has an additional drug candidate, KB001-A, a recombinant, PEGylated, anti-Pseudomonas PcrV high-affinity Fab antibody. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is based in Brisbane, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kalobios.com
News
Your note
Sign in to keep a note on KBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANTHION PARTNERS II LLC | Beneficial Owner (10% or more) | Purchase | Dec 15, 2015 | 378,210 |
| BARLIANT RONALD | Director | Acquisition (Non Open Market) | Jun 29, 2016 | 93,786 |
| BIESTEK MAREK | Director | Purchase | Dec 15, 2015 | 250,000 |
| CHAPPELL DALE | Director | Ownership Statement | Jun 29, 2016 | 0 |
| DURRANT CAMERON | Officer | Acquisition (Non Open Market) | Jun 29, 2016 | 135,583 |
| FERNANDEZ THOMAS EDWARD | Director | Purchase | Dec 15, 2015 | 6,821 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gerstein, Fisher & Associates, Inc. | 0.13% | 20,116 | 65.78K | Sep 29, 2016 |